3 Things About Ocugen That Smart Investors Know
Ocugen (NASDAQ: OCGN) has kept investors on the edge of their seats. Earlier in the year, a deal to co-commercialize Bharat Biotech's coronavirus vaccine in the U.S. equaled a 763% gain in the share price in a matter of weeks. Since that peak, the stock has retreated 47%. That's because the vaccine candidate -- Covaxin -- hasn't yet made it to the U.S. market.
Right now, you might be wondering whether the Ocugen story is over -- or whether now is the time to buy shares of this biotech stock. After all, if and when regulators give the nod to Covaxin, Ocugen shares may climb. Let's take a look at three things smart investors know about Ocugen before deciding.
Image source: Getty Images.
Source Fool.com